MX2021009821A - Terapia de combinación para el tratamiento de neoplasias malignas de células b. - Google Patents
Terapia de combinación para el tratamiento de neoplasias malignas de células b.Info
- Publication number
- MX2021009821A MX2021009821A MX2021009821A MX2021009821A MX2021009821A MX 2021009821 A MX2021009821 A MX 2021009821A MX 2021009821 A MX2021009821 A MX 2021009821A MX 2021009821 A MX2021009821 A MX 2021009821A MX 2021009821 A MX2021009821 A MX 2021009821A
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- combination therapy
- cell malignancies
- cell malignancy
- combination
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Hospice & Palliative Care (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Dermatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
En la presente descripción se proporcionan métodos para tratar una neoplasia maligna de células B y mutaciones génicas que pueden usarse para identificar sujetos que responderán al tratamiento de una neoplasia maligna de células B con una combinación de ibrutinib y un anticuerpo anti- PD-1.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962806148P | 2019-02-15 | 2019-02-15 | |
PCT/IB2020/051270 WO2020165861A1 (en) | 2019-02-15 | 2020-02-14 | Combination therapy for treatment of b-cell malignancies |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021009821A true MX2021009821A (es) | 2021-11-12 |
Family
ID=69740437
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021009821A MX2021009821A (es) | 2019-02-15 | 2020-02-14 | Terapia de combinación para el tratamiento de neoplasias malignas de células b. |
Country Status (15)
Country | Link |
---|---|
US (1) | US20200262925A1 (es) |
EP (1) | EP3923945A1 (es) |
JP (1) | JP2022520429A (es) |
KR (1) | KR20210129111A (es) |
CN (1) | CN113766918A (es) |
AU (1) | AU2020222359A1 (es) |
BR (1) | BR112021015964A2 (es) |
CA (1) | CA3129593A1 (es) |
EA (1) | EA202192256A1 (es) |
IL (1) | IL285458A (es) |
JO (1) | JOP20210225A1 (es) |
MA (1) | MA54941A (es) |
MX (1) | MX2021009821A (es) |
SG (1) | SG11202108770TA (es) |
WO (1) | WO2020165861A1 (es) |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2983670A4 (en) * | 2013-04-08 | 2017-03-08 | Pharmacyclics LLC | Ibrutinib combination therapy |
CN105848680A (zh) * | 2013-10-25 | 2016-08-10 | 药品循环有限责任公司 | 使用布鲁顿酪氨酸激酶抑制剂和免疫疗法的治疗 |
HUE059131T2 (hu) * | 2014-08-11 | 2022-10-28 | Acerta Pharma Bv | BTK-inhibitor, PD-1-inhibitor és/vagy PD-L1-inhibitor terápiás kombinációja |
WO2016128912A1 (en) * | 2015-02-12 | 2016-08-18 | Acerta Pharma B.V. | Therapeutic combinations of a btk inhibitor, a pi3k inhibitor, a jak-2 inhibitor, a pd-1 inhibitor, and/or a pd-l1 inhibitor |
CN108367006B (zh) * | 2015-12-04 | 2021-12-31 | 博尔托拉制药公司 | 用于治疗血液癌症的赛度替尼 |
CN110087680B (zh) * | 2016-08-19 | 2024-03-19 | 百济神州有限公司 | 使用包含btk抑制剂的组合产品治疗癌症 |
-
2020
- 2020-02-14 JP JP2021547345A patent/JP2022520429A/ja active Pending
- 2020-02-14 MX MX2021009821A patent/MX2021009821A/es unknown
- 2020-02-14 BR BR112021015964-9A patent/BR112021015964A2/pt unknown
- 2020-02-14 SG SG11202108770TA patent/SG11202108770TA/en unknown
- 2020-02-14 WO PCT/IB2020/051270 patent/WO2020165861A1/en unknown
- 2020-02-14 JO JOP/2021/0225A patent/JOP20210225A1/ar unknown
- 2020-02-14 CA CA3129593A patent/CA3129593A1/en active Pending
- 2020-02-14 KR KR1020217029364A patent/KR20210129111A/ko unknown
- 2020-02-14 US US16/791,217 patent/US20200262925A1/en active Pending
- 2020-02-14 EP EP20708643.0A patent/EP3923945A1/en not_active Withdrawn
- 2020-02-14 MA MA054941A patent/MA54941A/fr unknown
- 2020-02-14 EA EA202192256A patent/EA202192256A1/ru unknown
- 2020-02-14 AU AU2020222359A patent/AU2020222359A1/en active Pending
- 2020-02-14 CN CN202080029634.3A patent/CN113766918A/zh active Pending
-
2021
- 2021-08-09 IL IL285458A patent/IL285458A/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP3923945A1 (en) | 2021-12-22 |
JOP20210225A1 (ar) | 2023-01-30 |
MA54941A (fr) | 2021-12-22 |
KR20210129111A (ko) | 2021-10-27 |
SG11202108770TA (en) | 2021-09-29 |
EA202192256A1 (ru) | 2021-10-27 |
AU2020222359A1 (en) | 2021-09-02 |
BR112021015964A2 (pt) | 2021-10-05 |
JP2022520429A (ja) | 2022-03-30 |
US20200262925A1 (en) | 2020-08-20 |
CA3129593A1 (en) | 2020-08-20 |
WO2020165861A1 (en) | 2020-08-20 |
IL285458A (en) | 2021-09-30 |
CN113766918A (zh) | 2021-12-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2020012286A (es) | Metodos para tratar canceres y potenciar la eficacia de agentes terapeuticos para el redireccionamiento de celulas t. | |
MX2019011148A (es) | Metodos de tratamiento. | |
MX2017011834A (es) | Macrociclos peptidomimeticos y usos de los mismos. | |
MX2023001527A (es) | Compuestos con actividad inductora de ferroptosis y metodos de uso de estos. | |
EA201890961A1 (ru) | Комбинированная терапия для лечения злокачественных новообразований | |
EA201691683A1 (ru) | Антитела против dll3 и конъюгаты антитело-лекарственное средство для применения при меланоме | |
MX2022006701A (es) | Terapia combinada para el tratamiento de neoplasias malignas. | |
MX2022008868A (es) | Tratamiento del cancer con tg02. | |
PH12015500246A1 (en) | Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor | |
SG10201902594QA (en) | Peptidomimetic macrocycles and uses thereof | |
NZ725595A (en) | Compounds for treating brain cancer | |
ZA201803162B (en) | Combination therapy for treating malignancies | |
MX2020001727A (es) | Terapia de combinacion. | |
MX2021002241A (es) | Uso de linfocitos infiltrantes de tumor para tratar pacientes con carcinoma de pulmón de células no pequeñas (nsclc) refractario al anticuerpo anti muerte programada 1 (pd-1). | |
IL283298A (en) | Methods for dosage and treatment of B cell malignancies in adoptive cell therapy | |
NZ760756A (en) | Biomarkers for the diagnosis and treatment of fibrotic lung disease | |
MX2021003262A (es) | Metodos de tratamiento. | |
MX2021009821A (es) | Terapia de combinación para el tratamiento de neoplasias malignas de células b. | |
MX2023007680A (es) | Metodos de tratamiento y terapia de mantenimiento para el cancer de vejiga con gemcitabina. | |
MX2021006778A (es) | Metodo novedoso para el tratamiento del cancer mediante inmunomodulacion. | |
MX2021011529A (es) | Chiauranib para el tratamiento de cáncer de pulmón microcítico. | |
MX2021003734A (es) | Métodos de tratamiento del linfoma de linfocitos t periférico mediante terapia con conjugado fármaco-anticuerpo anti-cd30. | |
MX2021003265A (es) | Metodos de tratamiento. | |
ZA201907369B (en) | Treatment paradigm for an anti-cd19 antibody and venetoclax combination treatment | |
MX2022005250A (es) | Combinaciones terapeuticas de acalabrutinib y capivasertib para tratar neoplasias malignas de linfocitos b. |